MYC and B-cell chronic lymphocytic leukemia: Combination therapy appears to be a potential strategy, as there is evidence, for example, that GSI enhances the anti-leukemic activity of ibrutinib in CLL cells by down-regulating the Notch1 and c-Myc pathways [70].